PMID- 30302178
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220321
IS  - 1985-207X (Print)
IS  - 1985-2274 (Electronic)
IS  - 1985-2274 (Linking)
VI  - 13
IP  - 2
DP  - 2018
TI  - Achieving triple treatment goals in multi-ethnic Asian patients with type 2 
      diabetes mellitus in primary care.
PG  - 10-18
AB  - INTRODUCTION: Achieving optimal glycated hemoglobin (HbA1c), blood pressure (BP), 
      and LDL-Cholesterol (LDL-C) in patients mitigates macro- and micro-vascular 
      complications, which is the key treatment goal in managing type 2 diabetes 
      mellitus (T2DM). This study aimed to determine the proportion of patients in an 
      urban community with T2DM and the above modifiable conditions attaining triple 
      vascular treatment goals based on current practice guidelines. METHODS: A 
      questionnaire was distributed to adult Asian patients with dyslipidemia at two 
      primary care clinics (polyclinics) in northeastern Singapore. The demographic and 
      clinical data for this sub-population with both T2DM and dyslipidemia were 
      collated with laboratory and treatment information retrieved from their 
      electronic health records. The combined data was then analyzed to determine the 
      proportion of patients who attained triple treatment goals, and logistic 
      regression analysis was used to identify factors associated with this outcome. 
      RESULTS: 665 eligible patients [60.5% female, 30.5% Chinese, 35% Malays, and 
      34.4% Indians] with a mean age of 60.6 years were recruited. Of these patients, 
      71% achieved LDL-C </=2.6 mmol/L, 70.4% had BP <l40/90 mmHg, and 40.9% attained 
      HbAlc </=7%. Overall, 22% achieved the triple treatment goals for glycemia, BP, and 
      LDL-C control. The major determinants were the number of diabetic medications and 
      intensity of statin therapy. CONCLUSION: Eight in ten patients with T2DM failed 
      to achieve concurrent glycemic, BP, and LDL-C treatment goals, subjecting them to 
      risks of vascular complications. Primary healthcare professionals can mitigate 
      these risks by optimizing therapeutic treatment to maximize glycemia, 
      dyslipidemia, and BP control.
FAU - Goh, C C
AU  - Goh CC
AD  - B Pharm, SingHealth Polyclinics 167, Jalan Bukit Merah, Tower 5 #15-10, Singapore 
      150167 Email: goh.chin.chin@singhealth.com.sg.
FAU - Koh, K H
AU  - Koh KH
AD  - M.Med (Fam Med), MRCS., SingHealth Polyclinics.
FAU - Goh, Scp
AU  - Goh S
AD  - M.Med (Fam Med), FCFPS, SingHealth Polyclinics 167, Jalan Bukit Merah, Tower 5 
      #15-10, Singapore 150167.
FAU - Koh, Yle
AU  - Koh Y
AD  - BSc, SingHealth Polyclinics 167, Jalan Bukit Merah, Tower 5 #15-10, Singapore 
      150167.
FAU - Tan, N C
AU  - Tan NC
AD  - M.Med (Fam Med), FCFPS, SingHealth Polyclinics, Duke NUS Medical School, 
      Singapore.
LA  - eng
PT  - Journal Article
DEP - 20180831
PL  - Malaysia
TA  - Malays Fam Physician
JT  - Malaysian family physician : the official journal of the Academy of Family 
      Physicians of Malaysia
JID - 101466855
PMC - PMC6173958
OTO - NOTNLM
OT  - LDL-Cholesterol
OT  - Type 2 diabetes mellitus
OT  - blood pressure
OT  - normoglycemia
OT  - treatment goals
EDAT- 2018/10/12 06:00
MHDA- 2018/10/12 06:01
PMCR- 2018/08/31
CRDT- 2018/10/11 06:00
PHST- 2018/10/11 06:00 [entrez]
PHST- 2018/10/12 06:00 [pubmed]
PHST- 2018/10/12 06:01 [medline]
PHST- 2018/08/31 00:00 [pmc-release]
PST - epublish
SO  - Malays Fam Physician. 2018 Aug 31;13(2):10-18. eCollection 2018.